Click here for slides on this topic


Antihyperglycemic agents

Agents that treat diabetes by lowering blood glucose levels.
The following content matched the glossary term: Antihyperglycemic agents

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

T195-03

Top

Patient education handout describing what causes type 2 diabetes; the effects of diabetes on patient quality of life; and diabetes treatments.

Association between intensification of metformin treatment with insulin vs sulfonylureas and CV events and all-cause mortality among patients with diabetes

Top

Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311(22):2288-2296.

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin + MDI insulin

Top

Rosenstock J, Jelaska A, Frappin G, et al; on behalf of the EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014. DOI:10.2337/dc13-3055.

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

Top

Faillie J-L, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014;348:g2780. doi 10.1136/bmj.g2780.

NDEI.org Expert Commentary on Type 2 Diabetes Prevention in SEQUEL from Vivian Fonseca

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on type 2 diabetes prevention in a substudy of SEQUEL: “Weight loss alone may be an option to prevent type 2 diabetes”

1 2 3 4 5 Next 

Slide Library Results

Search Results for: Antihyperglycemic agents Slides Found: 25
Sites of Action of Oral Antihyperglycemic Agents
Sites of Action of Oral Antihyperglycemic Agents
Vildagliptin Monotherapy Improves Glycemic Control in Type 2 Diabetes
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
Duration of TZD Therapy Prior to Onset of Heart Failure
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
Guidelines for Children and Adolescents With Type 2 Diabetes: Insulin Therapy
Guidelines for Children and Adolescents With Type 2 Diabetes: Lifestyle Changes, Metformin for All
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (1 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (2 of 2)
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 2+ Compounds in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 1 Compound in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Number of Treatments
US Trends in Type 2 Diabetes Treatment, 1997-2012: Insulin Use
US Trends in Type 2 Diabetes Treatment, 1997-2012: Medication Classes
IDF Guidelines Type 2 Diabetes Diagnosis Older Adults Elderly | NDEI
Metformin Sulfonylureas Cancer Risk Type 2 Diabetes | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
TECOS Sitagliptin A1C Efficacy DPP-4 Inhibitor CV Safety | NDEI
Efficacy and Safety of Ranalozine on Glycemia in Type 2 Diabetes
Pharmacologic Therapy for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI